Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial

INTRODUCTION: The therapeutic options for thrombocytopenia in non-severe aplastic anaemia (NSAA) are limited. Avatrombopag (AVA) is prescribed for thrombocytopenic diseases but not for NSAA. METHODS: Herein, we conducted a phase 2, non-randomized, single-arm trial to explore the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Ziqi, Chen, Miao, Han, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274520/
https://www.ncbi.nlm.nih.gov/pubmed/37318085
http://dx.doi.org/10.1080/07853890.2023.2224044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274520/
https://www.ncbi.nlm.nih.gov/pubmed/37318085
http://dx.doi.org/10.1080/07853890.2023.2224044

Ejemplares similares